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Introduction {#sec005}
============

By the end of 2017, the World Health Organization (WHO) estimated that globally about 36.9 million people were living with HIV (PLHIV) and 1.8 million new infections occurred that year; over two thirds of the new infections were in Sub Saharan Africa (SSA) with about 50,000 in Uganda. During the same year, about 21.7 million (\~59%) of the PLHIV patients received antiretroviral therapy (ART) \[[@pone.0217606.ref001]\]. To accelerate epidemic control, the United Nations Joint Program on HIV/AIDS (UNAIDS) launched the 90-90-90 campaign in 2014. One of the targets was to achieve viral suppression among 90% of patients receiving ART by 2020 \[[@pone.0217606.ref002]\]. The other targets were ensuring that 90% of the people living with HIV know their HIV status and 90% of those who are diagnosed with HIV infection receive sustained ART. Treatment as prevention (TasP) studies have demonstrated effectiveness of ART in preventing new HIV infections \[[@pone.0217606.ref003]--[@pone.0217606.ref006]\]; therefore, increasing ART coverage has public health benefits including reduction of new HIV infections through reduced community viral loads. After two years of implementing the 2016 WHO and Uganda ministry of health (MoH) ART guidelines (T&T) \[[@pone.0217606.ref007],[@pone.0217606.ref008]\], there was a 32.5% increase in the number of patients receiving ART from about 890,000 in June 2016 to close to 1.2 million by June 2018 \[[@pone.0217606.ref009],[@pone.0217606.ref010]\]. Whereas achievement of the second and third UNAIDS targets demands timeliness in ART initiation, it is important that patients remain connected to the health care system for periodic drug refills and running of monitoring tests. Systematic reviews of studies on the rapidly expanding ART programs in SSA illustrated that about 60--65% of patients were retained in HIV care at 2 to 3 years after starting ART \[[@pone.0217606.ref011],[@pone.0217606.ref012]\]. A study done in Uganda among patients who started ART with a CD4 cell count \> 350 cells/ml found that at 2.5 years, 20% of patients were lost to follow up (LTFU) \[[@pone.0217606.ref013]\]. Similarly, the 2018 Uganda HIV/AIDS country progress report indicated suboptimal retention amongst ART naïve patients, with about 20% LTFU at 12 months \[[@pone.0217606.ref010]\]. Therefore, in settings where patients start ART immediately following a positive HIV test, there is the possibility that they may not return to the HIV clinics thereby offsetting the benefits associated with immediate initiation of treatment. Experiences from prevention of mother to child transmission (PMTCT) programs where immediate ART initiation has widely been practiced, among HIV infected mothers, indicate sub-optimal levels of ART adherence and retention of mothers in care, with majority being LTFU \[[@pone.0217606.ref014],[@pone.0217606.ref015]\]. LTFU has been associated with drug resistance, and comparatively poor long-term treatment outcomes, including mortality \[[@pone.0217606.ref016]\]. In this era of T&T, it is important that data characterizing retention of patients is available, especially in routine health care delivery settings. However, most of the data currently available are derived from implementation of test-and-treat in research settings \[[@pone.0217606.ref017]--[@pone.0217606.ref019]\]. In this study, we set out to study the cumulative incidence, incidence rate of loss to follow up, and factors associated with loss to follow up in a primary healthcare clinic that had been implementing the T&T policy since 2012.

Methodology {#sec006}
===========

Study design {#sec007}
------------

This was a retrospective cohort study utilizing data collected on patients who were diagnosed with HIV and enrolled into the HIV care program from January 2012 to 4^th^ July 2016 at the Uganda Cares clinic located within the Masaka regional referral hospital. A patient's ART initiation date defined the beginning of follow up (time zero) and follow up period was from 01^st^ January 2012 to 31^st^ December 2016. Patients with documented transfer out status contributed follow up time up to the date of transfer out. Patients' follow up ended if they died, transferred out to another HIV service delivery point, were LTFU or censored on 31^st^ December 2016.

Study site and settings {#sec008}
-----------------------

The Uganda Cares clinic serves as the main HIV outpatient department (OPD) clinic for Masaka regional referral hospital. The total catchment population for MRRH currently exceeds 2,000,000 people (according to the Uganda population and housing census-UPHC, 2014), distributed in almost ten districts. The HIV clinic runs five days a week and by the end of 2016, more than 13,000 clients were active in care, with more than **86%** starting ART. The clinic serves patients of all characteristics including sex workers from the various hot spots of the Kampala-Masaka-Mbarara high-way and from neighboring fishing communities.

HIV testing, linkage to care and initiation of ART in the study setting {#sec009}
-----------------------------------------------------------------------

At the beginning of 2012, provider initiated counseling and testing (PITC) was scaled up in MRRH. At the same time, voluntary counseling and testing (VCT) as well as home based HIV Counseling and Testing (HBHCT) outreaches were scaled up in the nearby villages. A serial HIV testing algorithm was used during the study period. For HIV screening, one of either Determine^™^ HIV-1/2 (Alere Medical Company Limited, Chiba, Japan) or INSTI ® HIV-1/2 antibody test (Biolytical laboratories, Richmond, Canada) was used depending on availability. Stat-Pak^®^ Dipstick (Chembio Diagnostic Systems, Medford, NY---USA) was used as a confirmatory test and Uni-Gold^™^ HIV (Trinity Biotech, Bray, Ireland) was used for tie breaking. Clients diagnosed with HIV within the hospital were enrolled into HIV care and encouraged to start ART immediately or shortly after. During this period, a stand-alone desk (focal desk at the HIV clinic) was set up to fast track treatment initiation. Patients diagnosed with HIV at the outreach sites were referred to this focal desk by trained counselors, to further aid and expedite ART initiation. Although the clinic begun piloting a T&T strategy at the beginning of 2012, it is important to note that this strategy wasn't a true manifestation of T&T as illustrated by the treatment as prevention (TasP) group, but rather a process where the ART initiation process was expedited, with the preparatory counseling phase taking a maximum of one week. Under this T&T strategy, point of care CD4 cell count and TB assessment were done within a week to further determine ART eligibility. However, patients who declined ART immediately or within seven days following HIV diagnosis, were initiated on ART at a time of their convenience with a similar array of services as their counterparts who started ART immediately or shortly after. Before June 2013, the MoH policy to start ART was based on CD4 cell ≤350 cells/ml or WHO clinical stages 3 or 4 \[[@pone.0217606.ref020]\]. From June 2013, HIV treatment guidelines have changed from starting ART based on CD4 cell count ≤500 cells/ml, WHO clinical stages 3 or 4 \[[@pone.0217606.ref021]\] to "treat all" regardless of CD4 cell count or WHO clinical stage \[[@pone.0217606.ref007],[@pone.0217606.ref008]\].

Study participants {#sec010}
------------------

We included all patients aged ≥18 years, tested HIV positive, who started ART anytime between 01^st^ January 2012 and 4^th^ July 2016, and were to be followed up at Masaka regional referral hospital. We excluded patients who were transferred in while on ART from other HIV clinics because we were not able to confirm their HIV test results and ART initiation dates with certainty, and patients with prior ART history (for example those that had ever used post exposure prophylaxis (PEP) since we could not ascertain the period when they were on medication).

Variables, data sources and measurement {#sec011}
---------------------------------------

The primary outcome was loss to follow up defined as failure of the client to show up at the Masaka clinic for at least 90 days from the date of their last scheduled appointment \[[@pone.0217606.ref022]\] taking 31^st^ December 2016 as the reference date. We determined loss to follow up by comparing a patients' most recent scheduled return visit date recorded into the electronic database with the reference date (31^st^ December 2016). The primary exposure (mode of treatment) was whether or not treatment was initiated within seven days following HIV diagnosis. Other extraneous variables included; patients' sex, age at ART initiation (determined by subtracting date of birth from the date of initiating ART), level of education, marital status, baseline CD4 cell count, baseline WHO stage, TB status at enrollment, ownership of a telephone set, and baseline body mass index (BMI) calculated using the baseline weight and height according to the formula BMI = weight/height (m)^2^. We initially developed a data extraction checklist and electronically retrieved a sample of records with the site data manager. We compared data in this pilot sample with the patients' files to ascertain the quality of data in the electronic database before we extracted the entire data set. Data were extracted in a Microsoft excel spread sheet, and cleaned. Where information was missing in the electronic database, the site data manager and two investigators retrieved patients' charts (source documents) and corrected the gaps, helped by a team of expert patients. For completely missing records, we employed multiple imputation by chained equation methods and we used Stata® version 13 for analysis.

Statistical methods {#sec012}
-------------------

We summarized patients' characteristics by medians (interquartile range) or mean (standard deviation) for continuous variables depending on the distribution, and percentages for categorical variables. Comparison of continuous and categorical baseline characteristics was done by using t-tests, Mann Whitney tests and chi-square or Fisher exact tests. We analysed data at bivariate level to estimate crude estimates or predictors of associations and multivariable cox regression modelling to estimate adjusted predictors of time to loss to follow up. Multivariable model building involved a stepwise approach. We included variables with a p value of \<0.2 at bivariate and dropped each turning out with a P\>0.05 at multivariable model building. Insignificant variables at this stage but highlighted in previous literature as significantly associated with LTFU were included in the final model. The proportion hazards (PH) assumption was evaluated for each of the variable included in the final model. Kaplan Meier survival curves were used to determine patients LTFU. In all statistical tests, a 5% level of significance was assumed.

Ethical considerations {#sec013}
----------------------

This study was retrospective and patients' consent could not be obtained. This was acknowledged and waived by the Makerere University School of Public Health Higher Degrees Research Committee which granted study clearance. We also sought approval from the management of the HIV clinic, to allow us have access to patients' data. Program data routinely collected and entered into an electronic records management system (OpenMRS) was extracted without patients' direct identifying information. These patients' data have been used solely for this current study, and cannot therefore be made publicly available.

Results {#sec014}
=======

Baseline characteristics {#sec015}
------------------------

During the period 1^st^ January 2012 to 4^th^ July 2016, data for 11,294 patients were extracted and 7,553 patients met the study inclusion criteria ([Fig 1](#pone.0217606.g001){ref-type="fig"}). Overall, there were more females (62.3%) than males. The median (IQR) age at initiation of ART was 30 (25--37) years with 20% starting ART at 40 years or above. Majority of patients were married (41.5%), had attained at least primary education (53.8%), weighed 45-60kg (62.1%), did not have a telephone set (50.9%), had no signs of tuberculosis (TB) (88.9%), started ART in WHO clinical stage 1 or 2 (85.5%), started treatment with Tenofovir Disoproxil Fumarate (TDF) based regimen (76.0%), and had a baseline body mass index (BMI) of 18.51--29.99 (75.7%). The median (IQR) CD4 cell count was 327 (180--485) cells/ml. Details of the baseline patients' characteristics are shown in [Table 1](#pone.0217606.t001){ref-type="table"}.

![A flow diagram showing patients abstraction and inclusion into the study and their outcomes.](pone.0217606.g001){#pone.0217606.g001}
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###### Patients background characteristics.

![](pone.0217606.t001){#pone.0217606.t001g}

  Characteristic                   Categories                                       All Groups                               
  -------------------------------- --------------- ---------------- --------------- ---------------- ------ ------ --------- ---------
  Sex                              Male            1099             38.6            1747             40.4   2846   37.7      0.339
  Female                           2132            66.0             2575            59.6             4707   62.3   \<0.001   
  Age (years)                      Median (IQR)    30 (25--37)      30 (25--38)     30 (25--37)                              
  18--24                           769             23.8             892             20.6             1661   22.0   0.117     
  25--29                           846             26.2             1064            24.6             1910   25.3   0.424     
  30--39                           987             30.6             1509            34.9             2496   33.1   0.026     
  40--49                           428             13.3             606             14.0             1034   13.7   0.747     
  50+                              201             6.2              251             5.8              452    6.0    0.859     
  Marital Status                   Never Married   204              6.3             318              7.4    522    6.9       0.630
  Married                          1447            44.8             1686            39.0             3133   41.5   0.001     
  Divorced/Separated               630             19.5             930             21.5             1560   20.6   0.339     
  Widowed                          43              1.3              80              1.9              123    1.6    0.806     
  Missing                          907             28.1             1308            30.3             2215   29.3   0.264     
  Education                        None            216              6.7             348              8.1    564    7.5       0.541
  Primary                          1648            51.0             2416            55.9             4064   53.8   0.002     
  Secondary                        965             29.9             1143            26.5             2108   27.9   0.083     
  Post-secondary                   149             4.6              155             3.6              304    4.0    0.660     
  Missing                          253             7.8              260             6.0              513    6.8    0.421     
  Has Telephone                    No              1337             41.4            2507             58.0   3844   50.9      \<0.001
  Yes                              1894            58.6             1815            42.0             3709   49.1   \<0.001   
  Baseline Weight (Kgs)            Mean (SD)       55 (10.9)        55 (10.5)       55(10.7)                                 
  \<45                             310             9.7              453             10.5             763    10.2   0.720     
  45--60                           1963            61.6             2692            62.5             4655   62.1   0.532     
  61+                              916             28.7             1163            27.0             2079   27.7   0.390     
  Baseline BMI                     ≤18.50          376              21.9            605              21.2   981    21.5      0.795
  18.51--29.99                     1293            75.3             2168            75.9             3461   75.7   0.691     
  ≥30                              48              2.8              83              2.9              131    2.9    0.974     
  Baseline CD4 cell count (μ/ml)   Median (IQR)    300 (171--440)   348(190--520)   327 (180--485)                           
  \<200                            932             30.9             1137            26.9             2069   28.5   0.045     
  200--350                         864             59.6             995             50.4             1859   25.7   \<0.001   
  ≥351                             1219            40.4             2100            49.6             3319   45.8   \<0.001   
  Baseline WHO clinical stage      1&2             2836             88.1            3605             83.6   6441   85.5      \<0.001
  3&4                              383             11.9             710             16.5             1093   14.5   0.042     
  TB status                        No signs        2961             91.6            3750             86.8   6711   88.9      \<0.001
  TB Suspect                       229             7.1              216             5.0              445    5.9    0.354     
  TB Diagnosed                     5               0.2              255             5.9              260    3.4    0.712     
  TB treatment                     18              0.6              90              2.1              108    1.4    0.666     
  Missing                          18              0.6              11              0.3              29     0.4    0.910     
  Baseline ART regimen             ABC based       14               0.4             10               0.2    24     0.3       0.932
  AZT based                        468             14.5             1317            30.5             1785   23.6   \<0.001   
  TDF based                        2747            85.0             2990            69.2             5737   76.0   \<0.001   
  Other                            2               0.1              5               0.1              7      0.1    0.999     
  Year of Starting ART             2012            292              9.0             1056             24.4   1348   17.9      \<0.001
  2013                             538             16.7             1253            29.0             1791   23.7   \<0.001   
  2014                             940             29.1             980             22.7             1920   25.4   0.001     
  2015                             993             30.7             782             18.1             1775   23.5   \<0.001   
  2016                             468             14.5             251             5.8              719    9.5    0.001     

Study outcomes {#sec016}
--------------

### a) Overall loss to follow up {#sec017}

There were 1180 cases of LTFU observed over 15,807.7 person years at risk. The overall incidence rate (IR) of LTFU was 7.5 (95% CI = 7.1--7.9) per 100 person years of observation (pyo). Cumulative incidence of LTFU was 8.9% (95% CI = 8.2--9.6%) at 6 months, 12.1% (95% CI = 11.3--12.9%) at 12 months, 15.8% (95% CI = 15.0%-16.7%) at 24 months, 18.0% (95% CI = 17.0--19.0%) at 36 months and 20.2% (95% CI = 19.0--21.4%) at 48 months. [Fig 2](#pone.0217606.g002){ref-type="fig"} shows the overall cumulative incidence of LTFU during the study period. [Fig 3](#pone.0217606.g003){ref-type="fig"} illustrates the proportion of patients LTFU by study group.

![Overall proportion of patients lost to follow up in the study period.](pone.0217606.g002){#pone.0217606.g002}

![Cumulative incidence of loss to follow up by study group at different time points.](pone.0217606.g003){#pone.0217606.g003}

### b) Incidence rate of loss to follow up by patients characteristics {#sec018}

[Table 2](#pone.0217606.t002){ref-type="table"} depicts detailed incidence rates (IR) of LTFU by patients' baseline characteristics, where the IR of LTFU was higher in the group that started ART within 7 days following diagnosis compared to the group that started ART after 7 days following diagnosis. The incidence rate of LTFU was highest in patients that started ART aged 18--24 years, highest in patients who were never married, highest in patients without a telephone set, highest in patients whose HIV disease was classified as either WHO stage 3 or 4 at baseline, highest among TB suspects at and highest among those whose baseline ART regimens were Abacavir (ABC) based.

10.1371/journal.pone.0217606.t002

###### Incidence rate of loss to follow up by patients characteristics.

![](pone.0217606.t002){#pone.0217606.t002g}

  Characteristic(s)                                Categories                                        Number of Cases   Person time   Rate/100PYO   95% CI   
  ------------------------------------------------ ------------------------------------------------- ----------------- ------------- ------------- -------- ------
  Overall study group                              1180                                              15807.7           7.5           7.1           7.9      
  Study Group                                      ART initiated within 7 days following diagnosis   598               5600.0        10.7          9.9      11.6
  ART initiated after 7 days following diagnosis   582                                               10207.8           5.7           5.3           6.2      
  Patient\'s Sex                                   Male                                              434               5943.5        7.3           6.6      8.0
  Female                                           746                                               9864.2            7.6           7.0           8.1      
  Age group (years)                                18--24                                            419               2913.7        14.4          13.1     15.8
  25--29                                           306                                               3939.9            7.8           6.9           8.7      
  30--39                                           312                                               5541.7            5.6           5.0           6.3      
  40--49                                           99                                                2386.0            4.1           3.4           5.1      
  50+                                              44                                                1026.4            4.3           3.2           5.8      
  Patient\'s Marital Status                        Never Married                                     103               982.2         10.5          8.6      12.7
  Married                                          477                                               6554.2            7.3           6.7           8.0      
  Divorced/Separated                               261                                               3042.7            8.6           7.6           9.7      
  Widowed                                          14                                                306.2             4.6           2.7           7.7      
  Missing                                          325                                               4922.5            6.6           5.9           7.4      
  Highest Education level attained                 None                                              110               1157.0        9.5           7.9      11.5
  Primary                                          641                                               8609.6            7.4           6.9           8.0      
  Secondary                                        311                                               4356.0            7.1           6.4           8.0      
  Post-secondary                                   30                                                675.3             4.4           3.1           6.4      
  Missing                                          88                                                1009.9            8.7           7.1           10.7     
  Whether Patient has Telephone                    No                                                701               8429.7        8.3           7.7      9.0
  Yes                                              479                                               7378.0            6.5           5.9           7.1      
  Baseline Weight (Kgs)                            \<45                                              128               1452.9        8.8           7.4      10.5
  45--60                                           770                                               9734.9            7.9           7.4           8.5      
  61+                                              253                                               4590.7            5.5           4.9           6.2      
  Baseline BMI                                     ≤18.50                                            141               1918.3        7.4           6.2      8.7
  18.51--29.99                                     467                                               7674.9            6.1           5.6           6.7      
  ≥30                                              5                                                 368.0             1.4           0.6           3.3      
  Baseline CD4 cell count (μ/ml)                   \<200                                             254               4344.0        5.8           5.2      6.6
  200--350                                         276                                               4165.7            6.6           5.9           7.5      
  ≥351                                             457                                               7195.0            6.4           5.8           7.0      
  Baseline WHO clinical stage                      1&2                                               998               13911.7       7.2           6.7      7.6
  3&4                                              173                                               1892.4            9.1           7.9           10.6     
  Patient\'s baseline TB status                    No signs                                          1036              14437.1       7.2           6.8      7.6
  TB Suspect                                       74                                                759.8             9.7           7.8           12.2     
  TB Diagnosed                                     36                                                411.2             8.8           6.3           12.1     
  TB Treatment                                     12                                                197.7             6.1           3.4           10.7     
  Baseline ART regimen                             ABC based                                         4                 32.9          12.2          4.6      32.4
  AZT based                                        237                                               5378.2            4.4           3.9           5.0      
  TDF based                                        938                                               10382.2           9.0           8.5           9.6      
  Other                                            1                                                 14.4              6.9           1.0           49.2     

### c) Factors associated with loss to follow up {#sec019}

[Table 3](#pone.0217606.t003){ref-type="table"} depicts the unadjusted and adjusted hazard rates of factors associated with LTFU. None of the variables included in the final model violated the PH assumption. At bivariate, patients who started ART within seven days following HIV diagnosis were 59% more likely to be lost to follow up (crude hazard ratio (cHR) = 1.59, 95% CI, 1.42--1.79).

10.1371/journal.pone.0217606.t003

###### Factors associated with loss to follow up.
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  Characteristic (s)                                Categories                                       crude Hazard Ratios   95% CI    P value   Adjusted Hazard Ratios   95% CI    P value
  ------------------------------------------------- ------------------------------------------------ --------------------- --------- --------- ------------------------ --------- ---------
  Study Group                                       ART initiated after 7 days following diagnosis   1.00                                      1.00                               
  ART initiated within 7 days following diagnosis   1.59                                             1.42--1.79            \<0.001   1.69      1.50--1.91               \<0.001   
  Patient\'s Sex                                    Male                                             1.00                                                                         
  Female                                            1.04                                             0.93--1.17            0.503                                                  
  Age group (years)                                 18--24                                           1.00                                      1.00                               
  25--29                                            0.58                                             0.50--0.67            \<0.001   0.57      0.49--0.66               \<0.001   
  30--39                                            0.43                                             0.37--0.50            \<0.001   0.41      0.35--0.48               \<0.001   
  40--49                                            0.32                                             0.26--0.40            \<0.001   0.30      0.24--0.37               \<0.001   
  50+                                               0.33                                             0.24--0.45            \<0.001   0.29      0.21--0.40               \<0.001   
  Patient\'s Marital Status                         Never Married                                    1.00                                      1.00                               
  Married                                           0.76                                             0.61--0.94            0.012     0.95      0.76--1.18               0.656     
  Divorced/Separated                                0.84                                             0.68--1.04            0.104     1.09      0.87--1.36               0.446     
  Widowed                                           0.55                                             0.33--0.92            0.023     0.97      0.57--1.64               0.896     
  Highest Education level attained                  None                                             1.00                                      1.00                               
  Primary                                           0.81                                             0.66--0.99            0.037     0.77      0.62--0.94               0.012     
  Secondary                                         0.77                                             0.62--0.95            0.017     0.65      0.52--0.82               \<0.001   
  Post-Secondary                                    0.50                                             0.34--0.75            0.001     0.50      0.34--0.75               0.001     
  Whether Patient has Telephone                     Yes                                              1.00                                      1.00                               
  No                                                1.39                                             1.24--1.57            \<0.001   1.52      1.35--1.71               \<0.001   
  Baseline CD4 cell count (μ/ml)                    \<200                                            1.00                                      1.00                               
  200--350                                          1.18                                             0.99--1.41            0.065     1.21      1.01--1.45               0.038     
  ≥351                                              1.10                                             0.95--1.28            0.202     1.13      0.96--1.32               0.133     
  Baseline WHO clinical stage                       1&2                                              1.00                                      1.00                               
  3&4                                               1.15                                             0.98--1.36            0.081     1.35      1.10--1.65               0.004     
  Patient\'s baseline TB status                     No signs                                         1.00                                      1.00                               
  TB Suspect                                        1.20                                             0.95--1.52            0.134     1.12      0.87--1.44               0.371     
  TB Diagnosed                                      1.02                                             0.73--1.42            0.924     1.12      0.76--1.64               0.559     
  TB Treatment                                      0.77                                             0.44--1.36            0.369     0.71      0.39--1.29               0.261     
  Baseline BMI                                      ≤18.50                                           1.00                                      1.00                               
  18.51--29.99                                      0.92                                             0.75--1.12            0.380     0.94      0.75--1.17               0.580     
  ≥30                                               0.50                                             0.31-.82              0.006     0.60      0.37--0.97               0.039     

In the multivariable analysis, the risk of LTFU was 69% higher in patients who started ART within seven days following HIV diagnosis compared to those who began ART after seven days (adjusted hazard ratio (aHR) = 1.69, 95% CI, 1.50--1.91). Patients who started ART at age 18--24 years were more likely to be LTFU compared with all the other age groups (aHR = 0.57, 95% CI, 0.49--0.66 for patients aged 25--29 years, aHR = 0.41, 95% CI, 0.35--0.48 for patients aged 30--39 years, and aHR = 0.29, 95% CI, 0.21--0.40 for patients aged 50 years or more). Compared to patients with no education, the risk of LTFU was least among patients who started ART with post-secondary education level (aHR = 0.50; 95% CI, 0.34--0.75). Patients without a telephone set were 52% more likely to be LTFU compared to those with a telephone set (aHR = 1.52, 95% CI, 1.35--1.71). Patients who started ART with HIV disease classified as WHO stage 3 or 4 were 35% more likely to be LTFU compared to those with WHO stage 1 or 2 (aHR = 1.35, 95% CI, 1.10--1.65). Patients who started ART with a baseline CD4 cell count of 200--350μ/ml were 21% more likely to be LTFU compared to those with a baseline CD4 cell count of \<200 μ/ml (aHR = 1.21, 95% CI, 1.01--1.45). Patients who started ART with a BMI of 30.0 or more, had a lower risk of LTFU compared to those who started ART with a BMI of \<18.50 (aHR = 0.60, 95% CI, 0.37--0.97) There was no association between patients' marital status and baseline TB assessment status with the risk of LTFU.

Discussion {#sec020}
==========

In this retrospective observation study in a primary healthcare clinic implementing the HIV T&T approach, we observed a higher cumulative incidence of LTFU in the entire study cohort. The LTFU rate was 7.5 per 100 years of observation. The likelihood of LTFU was higher among patients who started ART within seven days following an HIV diagnosis, were aged ≥25 years, did not have access to a telephone set, were less educated, had a baseline CD4 cell count of 200--350μ/ml and started ART with WHO stage categorized as either 3 or 4 or had a BMI of ≤18.50.

Four years after starting ART, one in every five patients (20.2%) who had started ART was LTFU. This falls short of the 2^nd^ UNAIDS target related to 90% of those diagnosed with HIV infection receiving sustained ART \[[@pone.0217606.ref002]\]. At 12 months after starting ART, we observed similar rates of loss to follow up as those reported by studies under the universal T&T setting \[[@pone.0217606.ref023],[@pone.0217606.ref017]\], and in other non T&T settings \[[@pone.0217606.ref024],[@pone.0217606.ref025]\]. Despite differences in the methodology and outcome definitions, we consistently observed an increasing cumulative incidence of LTFU with increase in years of treatment, similar to another study in South Africa \[[@pone.0217606.ref026]\]. To enhance long-term patient retention therefore, HIV programs must initiate concerted efforts that target the first months of treatment in ART-naïve patients. Besides, our findings also show an elevated risk of LTFU among patients who started ART within seven days following diagnosis compared to those who started after 7 days following HIV diagnosis. This finding contrasts what has been reported previously \[[@pone.0217606.ref027]\]. One possibility for the differences could be methodological, especially in the determination of the outcomes across the studies, but also the fact that different study populations were considered. Within the seven days, it is unconvincing that patients would have received enough counselling and consequently would have appreciated the benefit of starting ART when they were not yet "feeling sick" at diagnosis. Addressing structural bottle necks including counseling after a positive HIV test and before ART initiation have been identified as strategies for improving ART adherence and retention \[[@pone.0217606.ref028]\]. Before the T&T approach, the emphasis was that patients were taken through a minimum of three counselling sessions, were required to bring a treatment supporter, and had to demonstrate understanding of long term treatment by answering questions after counselling \[[@pone.0217606.ref029]\]. Currently however, ART is only delayed when there are co-infections with TB or Cryptococcal meningitis. All other patients' psycho-socio concerns are addressed along the treatment cascade during the subsequent clinic visits. It is therefore possible that some patients start ART when they have not fully accepted the benefits of early ART and the need to adhere to subsequent clinic visits. Therefore, in this T&T era, we suggest that ART programs initiate, and maintain an enhanced therapeutic education program throughout the HIV cascade to improve retention.

Between 2004 and 2012, ART was not commonly provided in health centers at level III (Health Centers at level three) \[[@pone.0217606.ref030]\]. In the Ugandan setting, these provide outpatient, maternity, general ward and laboratory services. However, at the beginning of 2013 and beyond, most health centers at level III were ART accredited. This is suggestive that a large number of patients formerly at Uganda Cares clinic might have opted to receive ART services at these centers without formally seeking transfers/referrals. Self-transfers across ART programs have been illustrated to conceal the actual proportion of patients categorized as LTFU in an Ethiopian study in a setting similar to ours \[[@pone.0217606.ref031]\]. The Uganda Cares clinic serves as the main HIV OPD clinic for the Masaka regional referral hospital, and therefore there is a possibility that patients diagnosed HIV positive on wards and started ART immediately or within 7 days, opted to receive ART at health facilities nearest to their usual dwellings once they got better. Furthermore, these patients could have died after starting ART but were never reported given the passive nature of surveillance in our setting. Under the Option B+ of PMTCT program, where immediate ART initiation has widely been practiced, patients' retention in such settings has remained sub optimal. And, initiation of ART on the same day of testing HIV positive was independently associated with an elevated risk of loss to follow up in the initial months of starting ART \[[@pone.0217606.ref015],[@pone.0217606.ref032]\].

Similar to a study done in Kenya \[[@pone.0217606.ref019]\], retention rates in all other age groups were better compared to adolescents or young adults (18--24 years). Retention in adolescents and young adults should be an important subject given the rising rates of infection in this particular sub population \[[@pone.0217606.ref033]\] and high rates of viral un-suppression \[[@pone.0217606.ref034]\]. If not at school, adolescents and young adults are usually at conflict with work schedules and most times fail to make routine monthly schedules, a requirement in most ART clinics. Similarly, clumping ART services of adults together with those of adolescents and young adults might blur individualized adolescent and young adults' needs. We anticipate that adolescents and young adults' groups might benefit from differentiated care models that address individualized patients' needs.

As seen from another study \[[@pone.0217606.ref035]\], patients with no education were more likely to be LTFU. Such patients might find it hard to read text reminder messages plus a couple of other information education communication (IEC) materials in health facilities that stress the need for continued care.

We observed that clients starting ART in WHO clinical stage 3 or 4 were more likely to be LTFU compared to those in stage 1 or 2. Among asymptomatic patients who started ART in South Africa, the proportion of LTFU was low \[[@pone.0217606.ref024]\]. Additionally, a reduced risk of death and improved retention rates were observed in a study assessing effectiveness of a streamlined model of care \[[@pone.0217606.ref023]\]. Patients categorized as stage 3 or 4 show higher likelihood of infections and are bed ridden most of the time. This is likely to make their continued engagement with the HIV clinic difficult. Such patients also have an increased risk of death especially in the first 6 months of ART due to severe immune reconstitution inflammatory syndrome and Cryptococcal meningitis \[[@pone.0217606.ref036],[@pone.0217606.ref037]\]. It is therefore possible that they died shortly after starting ART and never reported to the ART clinic again.

We observed that patients with a telephone set (mostly mobile phone) were less likely to be LTFU. In our setting, patients are sent short reminder text messages (SMS) before the clinic day and those who miss a clinic day are immediately called for a re-appointment. This cannot happen if one has no phone and so may lead to loss to follow up. Mobile phone technologies (mHealth), specifically SMS reminders have improved patient outcomes in other health service delivery settings \[[@pone.0217606.ref038]--[@pone.0217606.ref040]\] but were comparable to the standard of care for HIV retention in other settings \[[@pone.0217606.ref041],[@pone.0217606.ref022],[@pone.0217606.ref042]\]. It is however important to note that the level of interaction between provider and patient, and subset of activities under mHealth greatly determine the effectiveness of particular interventions. Therefore, interactive SMS reminders alone might not improve patient outcomes when compared to a combined strategy of SMS reminders, home visits and direct phone calls to patients.

Our observed association between baseline CD4 cell count and LTFU was consistent with findings from studies by Jain et al and Hønge et al \[[@pone.0217606.ref024],[@pone.0217606.ref043]\], despite differences in methodologies. We found a reduced likelihood of being LTFU among patients with high CD4 cell count (i.e, ≥ 351μ/ml). However, in a study by Mberi and colleagues \[[@pone.0217606.ref026]\], there was an elevated risk of LTFU among patients with a baseline CD4 cell count of \>200μ/ml. One possibility for this contrast could be a result of differences in the classification of a patient as LTFU but also immunological differences among study patients. Mberi et al classified patients as LTFU if they had spent at least 180 days without ART from the HIV clinic after a scheduled visit and this is different from our definition of LTFU. Similarly, our median (IQR) baseline CD4 cell count was high (327 (180--485)) compared to the best group in the study by Mberi et al of 87(36--150) \[[@pone.0217606.ref026]\]. Besides, patients with low CD4 cell counts are likely to be in WHO stage 3 or 4, a group prone to opportunistic infections and an elevated risk of mortality \[[@pone.0217606.ref036],[@pone.0217606.ref037]\]. It is therefore possible that patients with lower CD4 cell counts in our study were bed ridden or died shortly after initiation of ART and were never reported to the HIV clinic.

The effect of baseline BMI on LTFU in our study is similar to findings from two retrospective studies done in Guinea-Bissau and Malawi. Both studies established that a BMI of \<18.5kg/m^2^ was associated with an increased risk of LTFU \[[@pone.0217606.ref043],[@pone.0217606.ref044]\]. The low risk of LTFU we observed in over-weight patients could have arisen out of the enhanced counseling support offered in the non-communicable diseases (NCDs) clinic that was established during the course of the study. Health education messages in this clinic were tailored towards improving drug adherence as well as requiring patients to routinely visit the health facility for routine monitoring; and the clinic targeted patients with a higher risk of developing hypertension and diabetes. It is also possible that patients who were under-weight, developed opportunistic infections related to malnutrition and later died but were never reported to the HIV clinic due to the passive reporting mechanism. Moreover, a lower BMI has been reported to be correlated with HIV mortality and progression to AIDS \[[@pone.0217606.ref045],[@pone.0217606.ref046]\].

Limitations {#sec021}
-----------

Our study had limitations that should be taken into account while interpreting these findings. First, we utilized already collected data used for routine patient management. Such data presents with lots of gaps and sometimes may not present the rigor to warrant scientific research. Whereas this particular clinic is not a research site, it is part of the east African International epidemiology database to evaluate AIDS (IeDEA) consortium. As such, there are inherent data validation rules within the database and daily data cleaning to guarantee a certain degree of data correction and collation. Secondly, as it is in most HIV programs, there is a passive nature of surveillance and follow up of patients. There is therefore a possibility of having determined and regarded patients as lost to follow up in Masaka when they are actually in HIV care and receiving treatment somewhere else. This therefore, might have resulted in some over-estimation of the cumulative incidence rates of LTFU in our study. There is however a dedicated team at the facility that does contact tracing/case navigation for clients who miss clinic appointments, and we believe this might have minimized the misclassification. Lastly, the nature of data collected was limited. Some of the many health system (human resource, waiting time, distance) and socio-economic (type of work, socio contacts, HIV disclosure) factors known to affect LTFU were not studied. The effect of such under the current study settings remained unknown. We anticipate that, examining the effect of these under a T&T setting could better inform ART programing and policies towards boosting retention. Despite this study's limitations, the findings are likely to be generalizable to HIV positive patients who start ART in Uganda and in other resource-limited settings. Our study cohort was derived from a regional referral HIV clinic, therefore, it is highly possible that a wide scope of HIV patients with different background characteristics were studied. Furthermore, the HIV clinic to the largest extent exercises passive surveillance, a practice evident in most HIV care programs in Uganda.

Conclusions {#sec022}
===========

Our study showed that the risk of loss to follow up increased with time and was higher among patients who start ART within seven days following HIV diagnosis, higher among patients who lack access to a telephone, lower among patients aged ≥ 25 years, lower among patients with at least primary education, and lower among patients with BMI of ≥ 30. In this T&T era, there is need for HIV programs to initiate and maintain an enhanced therapeutic education program that target high risk groups, as well as leveraging on mHealth to improve patients' retention into care throughout the entire cascade of HIV care.
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